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Gilley et al. find that SARM1 promotes
axon degeneration after NMNAT2
depletion and limits outgrowth of axons
constitutively lacking NMNAT2. The
NMNAT substrate NMN also appears to
be pro-degenerative in both situations.
Restricted outgrowth of NMNAT2-
deficient axons is thus mechanistically
related to the degeneration of established
axons.
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SARM1 function and nicotinamide mononucleotide
adenylyltransferase 2 (NMNAT2) loss both promote
axon degeneration, but their relative relationship
in the process is unknown. Here, we show that
NMNAT2 loss and resultant changes to NMNAT me-
tabolites occur in injured SARM1-deficient axons
despite their delayed degeneration and that axon
degeneration specifically induced by NMNAT2
depletion requires SARM1. Strikingly, SARM1 defi-
ciency also corrects axon outgrowth in mice lacking
NMNAT2, independently of NMNATmetabolites, pre-
venting perinatal lethality. Furthermore, NAMPT inhi-
bition partially restores outgrowth of NMNAT2-defi-
cient axons, suggesting that the NMNAT substrate,
NMN, contributes to this phenotype. NMNAT2-
depletion-dependent degeneration of established
axons and restricted extension of developing axons
are thus both SARM1 dependent, and SARM1 acts
either downstream of NMNAT2 loss and NMN accu-
mulation in a linear pathway or in a parallel branch
of a convergent pathway. Understanding the
pathway will help establish relationships with other
modulators of axon survival and facilitate the devel-
opment of effective therapies for axonopathies.INTRODUCTION
Axon degeneration is a critical, early event in many neurode-
generative disorders. Studies of WLDS, an aberrant fusion
protein with critical nicotinamide mononucleotide adenylyl-
transferase (NMNAT) activity responsible for the slow Wallerian
degeneration phenotype, indicate this often shares molecular
features with injury-induced axon degeneration (Conforti
et al., 2014). New, endogenous regulators of Wallerian degen-
eration have emerged, so establishing interactions among
them will be important for developing appropriate therapies
(Conforti et al., 2014; Neukomm and Freeman, 2014; Pease
and Segal, 2014). While a conserved pathway is emerging,
the relationship between NMNAT2 and sterile alpha and TIR
motif containing 1 (SARM1), key regulators of axon degenera-1974 Cell Reports 10, 1974–1981, March 31, 2015 ª2015 The Authortion with opposing influences, is still unknown (Conforti et al.,
2014).
NMNAT2 is one of three naturally occurring mammalian
NMNATs. Like WLDS, each robustly delays Wallerian degenera-
tion when re-localized or sufficiently overexpressed (Mack et al.,
2001; Milde et al., 2013; Sasaki et al., 2009; Yahata et al., 2009),
but only depletion of NMNAT2, not NMNAT1 or NMNAT3, trig-
gers WLDS-sensitive neurite degeneration in neuronal cultures
(Gilley and Coleman, 2010). This suggests NMNAT2 is the iso-
form that contributes most to axon survival in a physiological
context. Drosophila NMNAT ortholog, dNmnat, appears to
have a similar role in flies (Fang et al., 2012). Early loss of
short-lived NMNAT2 in injured axons, prior to frank degenera-
tion, has thus been proposed as a trigger for WLDS-sensitive
axon degeneration and the point of WLDS influence (Conforti
et al., 2014; Gilley and Coleman, 2010). This is supported by
studies that show that a critical requirement for PHR1/Highwire
ubiquitin ligase during Wallerian degeneration may be linked to
its regulation of NMNAT2/dNmnat turnover (Babetto et al.,
2013; Xiong et al., 2012) and the proposal that accumulation of
the NMNAT substrate NMN, a predicted consequence of
NMNAT2 loss, acts as a pro-degenerative signal (Di Stefano
et al., 2014). Severe truncation of peripheral nerve axons and
CNS axon tracts in NMNAT2-deficient embryos, likely respon-
sible for their perinatal lethality, is also consistent with a critical
axon survival function for NMNAT2 in vivo (Gilley et al., 2013;
Hicks et al., 2012). Importantly, though, this developmental
phenotype appears to be primarily due to an initial outgrowth
defect rather than dying-back degeneration of established axons
(Gilley et al., 2013).
SARM1, in contrast, has a pro-degenerative function. It is
required for the normal, rapid progression of degeneration after
injury and other WLDS-sensitive insults (Gerdts et al., 2013; Os-
terloh et al., 2012). Multimerization, mediated by its SAM (sterile
a motif) domain, appears to be required for a pro-degenerative
function dependent on its TIR (Toll-interleukin-1 receptor)
domain (Gerdts et al., 2013). Crucially, SARM1 depletion is
currently the only known manipulation that delays WLDS-sensi-
tive axon degeneration as robustly as expression of WLDS or
other NMNATs.
In this study, we used axon injury in nerves and neurons
from Sarm1/ mice to establish the relationship between
NMNAT2 loss and a SARM1-dependent function during
WLDS-sensitive degeneration. Remarkably, we also find that
mice lacking both NMNAT2 and SARM1 are viable, enablings
Figure 1. SARM1 Acts Downstream of NMNAT2 Loss during Axon Degeneration
(A) Representative immunoblot of uncut (0 hr) and 4-hr-cut wild-type and Sarm1/ SCG neurite extracts probed for NMNAT2 and b-actin (sample control).
NMNAT2 migrates at 32 kDa. Quantification of normalized NMNAT2 levels (to b-actin), is shown below with 4-hr data presented relative to uncut (set at 1).
Means ± SEM are plotted (n = 3; p = 0.86 wild-type versus Sarm1/ at 4 hr).
(B) NMN and NAD levels in uncut, and 30-hr- or 120-hr-lesioned wild-type and Sarm1/ sciatic nerves. Means ± SEM are plotted (n = 3–5). Levels in 120-hr-cut
wild-type nerves were not determined (ND) as their axons are degenerated.
(C) Representative images of distal neurites of wild-type and Sarm1/ SCG neurons 24 and 72 hr after injection with 100 ng/ml Nmnat2 siRNA (siNmnat2) and
10 ng/ml pEGFP-C1 (expressed EGFP allows visualization of the neurites of injected neurons).
(D) Quantification of survival of wild-type (WT) and Sarm1/ SCG neurites (left) and cell bodies (right) for 3 days after injection with pEGFP-C1 and siNmnat2 or
non-targeting siRNA (siNT) as in (C). Means ± SEM are plotted (n = 3–4).us to examine the mechanistic origins of the developmental
axon outgrowth defect associated with constitutive NMNAT2
deficiency.
RESULTS
SARM1 Promotes Axon Degeneration Downstream
of NMNAT2 Loss
NMNAT2 levels have previously been found to decline rapidly in
the distal stumps of transected wild-type SCG and DRG neurites
prior to their degeneration at 8 hr (Gilley and Coleman, 2010;
Yang et al., 2013). Here, we find equivalent loss of NMNAT2 in
wild-type and Sarm1/ SCG neurites by 4 hr after cut (Fig-
ure 1A), even though degeneration of transected Sarm1/ neu-
rites is delayed for at least 3 days (Osterloh et al., 2012). Levels ofCellthe NMNAT substrate, NMN, and product, NAD, have also been
shown to respectively rise and fall in the distal stumps of trans-
ected wild-type sciatic nerves (Di Stefano et al., 2014) prior to
axon degeneration, which occurs at around 36 hr (Beirowski
et al., 2005). This is consistent with a predicted loss of NMNAT2
in injured axons in vivo. Here, we find that these changes are not
prevented in Sarm1/ nerves at 30 hr after lesion (Figure 1B),
despite Sarm1/ axons being preserved for at least 14 days
(Osterloh et al., 2012). In fact, by 30 hr, NMN has risen signifi-
cantly more than in wild-type nerves, and by 120 hr, NAD levels
have dropped below those in wild-type nerves at 30 hr (a short
time before they degenerate). Together, these data suggest
SARM1 promotes Wallerian degeneration downstream or inde-
pendently of NMNAT2 loss and consequent changes in NMN
and NAD levels.Reports 10, 1974–1981, March 31, 2015 ª2015 The Authors 1975
Figure 2. Normal Development and Survival of Nmnat2gtE/gtE;Sarm1/ Mice
(A) Neurofilament-L immunostaining of diaphragms from E18.5 Nmnat2gtE/gtE and Nmnat2gtE/gtE;Sarm1/ embryos (montages representative of n = 3 for each
genotype). Boxed areas are magnified (right). Distal branches of phrenic nerves were present in wild-type, Nmnat2+/gtE, Sarm1/, and Nmnat2+/gtE;Sarm1/
embryos as expected (not shown).
(B) DiI-labeled intercostal nerves in ribcages from P0 Nmnat2gtE/gtE and Nmnat2gtE/gtE;Sarm1/ pups (montages, representative of n = 3 for each genotype).
Nerve truncation was seen in all Nmnat2gtE/gtE pups but was rescued in all Nmnat2gtE/gtE;Sarm1/ pups.
(C) Quantification of radial neurite outgrowth over 7 days for E18.5 SCG explant cultures of the genotypes listed. Means ± SEM are plotted (n = 3–6 embryos of
each genotype, average of both ganglia). Extension of the majority of Nmnat2gtE/gtE neurites (mass) and a more robust sub-population (max) are both shown.
(legend continued on next page)
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Although NMNAT2 loss has been strongly implicated as a
trigger for Wallerian degeneration, this is difficult to prove defin-
itively, as injury induces many simultaneous changes. We
therefore assessed whether SARM1 is required during related,
WLDS-sensitive axon degeneration induced specifically by
small interfering RNA (siRNA)-mediated depletion of NMNAT2
(Gilley and Coleman, 2010). We found distal neurites of
Sarm1/ neurons are completely protected from Nmnat2
siRNA-induced degeneration for at least 72 hr, and also from
the later, slower loss of cell viability (Figures 1C and 1D).
NMNAT2 depletion can thus trigger SARM1-dependent axon
degeneration in the absence of injury or other initiating stimuli
supporting a situation in which either SARM1 itself, or a
SARM1-dependent activity of a convergent pathway, promotes
WLDS-sensitive axon degeneration downstream of NMNAT2
loss.
SARM1 Promotes Axon Defects in Mice Lacking
NMNAT2
We next bred mice doubly homozygous for the Nmnat2gtE gene
trap allele (effectively a null allele; Gilley et al., 2013) and a Sarm1
knockout allele (Kim et al., 2007) to investigate whether SARM1
might also contribute to axon defects associated with constitu-
tive NMNAT2 deficiency during development.
Intriguingly, whole-mount labeling of distal phrenic nerve
branches in the diaphragm and of intercostal nerves in
Nmnat2gtE/gtE;Sarm1/ embryos/newborn pups revealed clear
and reproducible rescue of the peripheral nerve axon truncation
defect associated with NMNAT2 deficiency in Nmnat2gtE/gtE an-
imals (Figures 2A and 2B). The underlying cause of this defect in
Nmnat2gtE/gtE embryos is restricted axon extension (Gilley et al.,
2013); therefore, to obtain a quantitative measure of rescue by
SARM1 deficiency, we compared neurite outgrowth in SCG
explant cultures fromNmnat2gtE/gtE andNmnat2gtE/gtE;Sarm1/
embryos with that of relevant controls (Figures 2C and 2D). Strik-
ingly, Nmnat2
gtE/gtE
;Sarm1/ neurite outgrowth matched that in
Sarm1/ and Nmnat2+/gtE;Sarm1/ littermate cultures, as
well as in wild-type and Nmnat2+/gtE cultures assessed in paral-
lel. Similar rescue was also seen in DRG cultures (not shown).
The axon extension defect associated with a lack of NMNAT2
thus appears fully corrected in late-stage embryos and
newborn mice deficient for SARM1. Consistent with this, while
Nmnat2gtE/gtE (and Nmnat2gtE/gtE;Sarm1+/) pups die at birth,
Nmnat2gtE/gtE;Sarm1/ mice in contrast are viable and reach
weaning at the expected Mendelian ratios (Figure 2E). Adult
Nmnat2gtE/gtE;Sarm1/ mice are also fertile and, despite subtle
gender- and Sarm1-genotype-specific differences, their weights
at 10 weeks are within a healthy range and similar to control(D) Representative images of Nmnat2gtE/gtE and Nmnat2gtE/gtE;Sarm1/ neurite
extension of Nmnat2gtE/gtE neurites are marked (continuous and dashed lines).
(E) Viability of offspring from Nmnat2+/gtE or Nmnat2+/gtE;Sarm1/ crosses.
(F) Weights of 10-week-old male or female Nmnat2gtE/gtE;Sarm1/ mice relativ
plotted. The weights of different genotypes in control groups do not vary signific
(G) Representative RT-PCR analysis ofNmnat2,Sarm1, andActb (sample control)
of normalized Nmnat2 levels (to Actb), relative to wild-type levels, is shown belo
(H) Representative immunoblots (of n = 3) showing NMNAT2, SARM1, and ßIII-tu
genotypes.
Cellgroups (Figure 2F). Crucially, RT-PCR and immunoblotting
confirmed that the Nmnat2gtE allele remains effectively silenced
on a Sarm1/ background (Figures 2G and 2H). This rules out
reduced efficacy of the gene trap as being responsible for rescue
of the phenotype.
As in injured nerves, SARM1 deficiency does not prevent ex-
pected changes to NMNAT metabolites in the brains of embryos
lacking NMNAT2 (Figure 3A). In fact, the relative increase in
NMN in Nmnat2gtE/gtE;Sarm1/ brains is greater than in
Nmnat2gtE/gtE brains, presumably due to rescued outgrowth of
CNS axons, where changes, away from the influence of nuclear
NMNAT1, should be greatest. A small, but significant, reduction
in NAD is also evident in Nmnat2gtE/gtE;Sarm1/ brains. In
contrast, heterozygosity for the Nmnat2gtE allele does not signif-
icantly alter brain NMN or NAD levels on either Sarm1 back-
ground. Interestingly, there is a trend toward higher NMN and
NAD levels in Sarm1/ brains, independent of NMNAT2-related
changes, and the total adenylate pool (ATP + ADP + AMP) is
increased (1,764 ± 113 nmol/g tissue in Sarm1/ brains
compared to 1,314 ± 97 in Sarm1+/+ brains; p = 0.009). Thus,
SARM1 itself may have some influence over NAD and/or energy
metabolism.
In case the complexity of whole brain concealed more marked
changes specifically in axons, we also assessed nucleotide
levels separately in DRG neurites and ganglia (Figures 3B and
S1). Indeed, consistent with NMNAT2 being the major axonal
NMNAT, we detected a greater relative increase in NMN and
decrease in NAD in Nmnat2gtE/gtE;Sarm1/ neurites than in
brains. In contrast, changes in ganglia fractions were far more
modest, indicating NMNAT2 has less influence in the cell body
(and associated proximal neurite stumps). Surprisingly, accu-
mulation of NMN was not evident in the limited neurite
outgrowth in Nmnat2gtE/gtE cultures. However, the NMN/NAD
ratio is increased to the same extent as in Nmnat2gtE/gtE;
Sarm1/ neurites, due to a much greater reduction in NAD,
consistent with comparable loss of NMNAT activity. We specu-
late that, even though stunted Nmnat2gtE/gtE neurites do not
show signs of overt degeneration, their integrity could still be
compromised, resulting in NMN and NAD efflux and the lower
than expected levels of both nucleotides. Low NAD in
Nmnat2gtE/gtE ganglia fractions suggests this may also extend
to proximal neurite stumps and possibly even cell bodies.
Finally, as in brains, heterozygosity for the Nmnat2gtE allele
does not significantly alter NMN and NAD levels in either DRG
fraction. This is consistent with overt normality of Nmnat2+/gtE
axons in both contexts.
Overall, these results indicate that SARM1 is critically involved
in the manifestation of the phenotype ofNmnat2gtE/gtE mice, withoutgrowth at 7 days in vitro in E18.5 SCG explant cultures. Mass and max
e to indicated control groups. Both individual weights and means ± SEM are
antly.
mRNA levels in E18.5 embryo brains of the indicated genotypes. Quantification
w. Means ± SEM are plotted (n = 3).
bulin (sample control) expression in brains from E18.5 embryo of the indicated
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Figure 3. NMN and NAD Changes Resulting
from a Lack of NMNAT2 during Develop-
ment Occur in the Absence of SARM1
(A) NMN and NAD levels (nmol/g tissue) and NMN/
NAD ratios in brains from E18.5 embryos/P0 pups
of the indicated genotypes. Means ± SEM are
plotted (n = 5–7 each genotype). Data for samples
wild-type for Sarm1 (red tones) have been pre-
sented previously in a different format (Di Stefano
et al., 2014). Re-use of the same dataset here al-
lows direct comparison with the Sarm1/ back-
ground data (blue tones), which was obtained in
parallel.
(B) NMN and NAD levels (nmol/mg extracted pro-
tein) and NMN/NAD ratios in separate neurite or
ganglia fractions from 7-days-in-vitro explant cul-
tures of DRGs from E13.5/14.5 embryos of the
indicated genotypes. Ganglia fractions contain
short proximal neurite stumps as well as cell
bodies. Means ± SEM are plotted (n = 3–5 each
genotype). See also Figure S1, where data in (B)
are presented as relative changes.it, or a dependent activity, acting downstream of predominantly
axonal alterations to NMN and NAD resulting from the lack of
NMNAT2. Crucially, this suggests significant mechanistic over-
lap between WLDS-sensitive axon degeneration and the axon
outgrowth defect in these mice.
NMN Contributes to the Limited Outgrowth
of NMNAT2-Deficient Neurites
We have previously implicated rising NMN, rather than declining
NAD, as a critical pro-degenerative event in injured axons, in part
by showing that blocking NMN synthesis with NAMPT inhibitor
FK866 and scavenging NMN via ectopic expression of bacterial
NMN deamidase (converting it to NaMN) both delay Wallerian
degeneration (Di Stefano et al., 2014). We therefore used these
reagents to investigate whether NMN also limits outgrowth and
survival of axons lacking NMNAT2.
First, we tested the prediction that survival of Nmnat2gtE/gtE;
Sarm1/ SCG neurites should be impaired by ectopic re-
expression of SARM1 due to re-activation of a SARM1-depen-
dent degeneration pathway downstream of NMNAT2 deficiency,
and assessed whether these events are NMN-dependent using
co-expression of NMN deamidase (Figures 4A and 4B). While
ectopic re-expression of SARM1 (C-terminal GFP tagged) in
Sarm1/ neurons (with normal NMNAT2) unexpectedly induced
some neurite degeneration by 24 hr, it induced much more
extensive degeneration of Nmnat2gtE/gtE;Sarm1/ neurites
(lacking NMNAT2) and, crucially, this was significantly reduced
by co-expression of NMN deamidase (N-terminal GFP tagged).
This suggests that, as well as promotingWallerian degeneration,
NMN also drives SARM1-dependent degeneration in this1978 Cell Reports 10, 1974–1981, March 31, 2015 ª2015 The Authorscontext. Importantly, these experiments
additionally confirm that rescue of
Nmnat2gtE/gtE;Sarm1/ axons is due to
SARM1 deficiency and not other, unde-
fined changes resulting from mouse
breeding.Next, we used FK866 to assess whether NMN accumulation
also limits Nmnat2gtE/gtE neurite outgrowth (Figures 4C and
4D). Interestingly, FK866 stimulated additional outgrowth of
Nmnat2gtE/gtE DRG neurites, but only for about 24 hr, after which
neurites underwent complete degeneration. Because FK866
causes simultaneous reductions to both NMN and NAD in
neuronal cultures (Di Stefano et al., 2014), we considered that
this later degeneration could be due to an extreme reduction in
NAD in neurites now lacking both NAMPT and NMNAT2 activ-
ities and/or secondary to neuronal death caused by reduced
somal NAD. To overcome this, we co-treated cultures with po-
tential sources of NAD. NAD itself was ineffective (Figure S2),
likely due to inefficient entry into neurons and/or failed conver-
sion of more readily internalized NAD precursors (generated by
extracellular degradation) back into NAD when NMNAT2 is
absent (Di Stefano et al., 2014; Nikiforov et al., 2011), possibly
even leading to further NMN accumulation in Nmnat2gtE/gtE
neurites. However, NaAD, an alternative source of NAD via
endogenous NAD synthetase (Di Stefano et al., 2014), did pro-
mote additional outgrowth and survival of Nmnat2gtE/gtE neurites
when added with FK866 (but, importantly, not when added
alone). Together, these data suggest increased NMN does
contribute to the restricted outgrowth of Nmnat2gtE/gtE neurites,
although rescue of Nmnat2gtE/gtE neurite outgrowth by FK866
and NaAD still falls some way short of the outgrowth of wild-
type neurites treated in the same way (despite this also being
slightly inhibitory) (Figure 4C). Therefore, either inhibition of
NAMPT by FK866 or clearance of pre-accumulated NMN is rela-
tively ineffective and/or outgrowth is not exclusively limited by
NMN-dependent events.
Figure 4. Pharmacological and Genetic In-
hibition of NMN Accumulation Promotes
Growth and Survival of NMNAT2-Deficient
Neurites
(A) Representative images of neurites of Sarm1/
or Nmnat2gtE/gtE;Sarm1/ SCG neurons 24 hr af-
ter injection with 6.25 mg/ml Texas red dextran (for
rapidly labeling neurites of injected neurons)
together with 40 ng/ml GFP-NMN deamidase
expression construct and 10 ng/ml pEGFP-C1
(GFP-NMNd (& GFP)), 10 ng/ml SARM1-GFP
expression construct and 40 ng/ml pEGFP-C1
(SARM1-GFP (& GFP)), or 10 ng/ml SARM1-GFP
and 40 ng/ml NMN deamidase-GFP expression
constructs (SARM1-GFP & GFP-NMNd). SARM1-
GFP induces degeneration of the proximal 1–
2 mm of neurites, presumably shortly after exiting
the soma.
(B) Quantification of neurite survival in experiments
described in (A). Means ± SEM are plotted (n = 3–7
each treatment). Neurite survival after GFP-NMNd
(& GFP) expression is not significantly different
from GFP alone (not shown).
(C) Quantification of neurite outgrowth over 7 days
for explant cultures of DRGs taken from E18.5
Nmnat2gtE/gtE embryos (left) or wild-type embryos
(right) treatedwith FK866 and/or NaAD after 2 days
in vitro. Means ± SEM are plotted (n = 3–6 each
treatment, statistical significance shown relative to
untreated).
(D) Representative phase contrast images
showing the physical appearance of treated
Nmnat2gtE/gtE DRG neurites (if present) at 5 days
in vitro (3 days after compound addition). See also
Figures S2 and S3.DISCUSSION
Despite their shared ability to profoundly influence axon survival
after injury, no link between NAD metabolism and SARM1 func-
tion had previously been firmly established. Our studies show
not only that either SARM1 itself, or a SARM1-dependent
convergent activity, acts downstream of NMNAT2 loss and re-
sulting changes to key NMNAT metabolites to promote WLDS-
sensitive axon degeneration but also that this also occurs
downstream of NMNAT2 deficiency and dependent changes
during development to impair axon outgrowth and limit mouse
survival. Intriguingly, an NMNAT2 depletion-dependent accumu-
lation of NMNAT substrate, NMN, also appears to be a critical
pro-degenerative signal in both situations (this study; Di Stefano
et al., 2014), strongly suggesting they are eachmediated by acti-
vation of the same NMN- and SARM1-dependent degeneration
pathway. Importantly, our data appear to rule out any lasting sta-
bilization of NAD or reduced accumulation of NMN as part of the
mechanism underlying protection of SARM1-deficient axons,
although intriguing increases in total adenylate pool and
steady-state levels of NMN and NAD in Sarm1/ brains may
yet be found to be involved.
Overall, our studies suggest either that changes resulting from
NMNAT2 loss directly activate a pro-degenerative SARM1 func-
tion in axons in a linear pathway or that parallel SARM1-depen-
dent and NMNAT2 loss-dependent signals merge at a commonCelldownstream step in a convergent pathway (Figure S3). Impor-
tantly, the critical SARM1-dependent event in either model likely
acts upstream of calpain activation (Yang et al., 2013). Given that
NMNAT2 depletion alone can activate SARM1-dependent neu-
rite degeneration, the convergent pathway model would appear
to require that SARM1 has constitutive pro-degenerative activity,
with activation or disinhibition of a critical downstream step only
occurring after NMNAT2 loss. While a proposed regulatory role
for the N-terminal domain of SARM1 (Gerdts et al., 2013) ap-
pears more consistent with activation of a pro-degenerative
function in a linear pathway, our finding that exogenous expres-
sion of SARM1(-GFP) induces some degeneration even when
NMNAT2 is present (in Sarm1/ neurons) suggests it could
have some constitutive pro-degenerative activity (although con-
ditions in these assays could also influence this outcome). Un-
derstanding precisely how endogenous SARM1 functions in
the context of NMNAT2 loss and NMN accumulation during
axon degeneration, and how this relates to other cellular roles
of SARM1 (Conforti et al., 2014), will therefore be an important
goal for future studies.
We had previously proposed that the early, limited extension
of axons lacking NMNAT2 reflects restricted supply of an
NMNAT-activity-dependent molecule required for axon growth,
with NAD being a prime candidate (Gilley et al., 2013). However,
initially improved outgrowth of Nmnat2gtE/gtE neurites further
deprived of NAD by FK866 challenges this idea, and theReports 10, 1974–1981, March 31, 2015 ª2015 The Authors 1979
involvement of SARM1 instead suggests these neurites stop ex-
tending at the point where SARM1-dependent degeneration be-
comes active. In light of our findings, we speculate that NMN
concentration may determine this activity. We predict that, due
to a diminishing influence of nuclear NMNAT1, NMN in
NMNAT2-deficient axons will rise as a function of distance
from the soma, with some axon outgrowth possible up to the
point at which a critical threshold is exceeded and SARM1-
dependent degeneration is triggered.
NAD plays a key role in many diverse cellular functions (Di Ste-
fano and Conforti, 2013), so the fact that significant reductions in
NAD do not prevent the delayed degeneration of cut SARM1-
deficient axons or limit the normal growth and survival of intact
axons lacking both NMNAT2 and SARM1 (in culture and in
mice) was somewhat surprising. This, together with the ability
of FK866 to delay degeneration of cut axons (Di Stefano et al.,
2014) and temporarily rescue Nmnat2gtE/gtE neurite outgrowth,
despite further depletion of NAD, clearly indicates that fairly sub-
stantial reductions in NAD are not necessarily detrimental. How-
ever, it would be surprising if greater NAD depletion did not limit
axon survival in some situations.
On its own, survival ofNmnat2gtE/gtE;Sarm1/mice for several
monthswith noovert problems suggests very strongcorrectionof
the defects associatedwith constitutive NMNAT2 deficiency dur-
ing early development. However, it will still be critical to establish
the precise extent and duration of this rescue in an aging study.
Nevertheless, these mice already represent a unique resource
for the identification or confirmation of other early pro-degenera-
tive events triggered by NMNAT2 loss and NMN accumulation,
given that our data suggest an activated degeneration pathway
ispausedataSARM1-dependent step inNmnat2gtE/gtE;Sarm1/
axons. For example, SARM1 appears to act downstream of reac-
tive oxygen species accumulation, ATP depletion, and Ca
2+
influx
when cell death and axon degeneration are induced by the mito-
chondrial toxin carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) (Summers et al., 2014), but it will be important to establish
whether these changes also occur downstream of NMNAT2 loss
duringWLDS-sensitive degeneration. They should also be partic-
ularly useful for studying non-axonal phenotypes associated with
NMNAT2deficiency thatmaybeSARM1 independent, such as its
role in cardiac hypertrophy (Cai et al., 2012).
To conclude, these studies have now firmly established the
order of two core events in an emerging WLDS-sensitive and
SARM1-dependent axon degeneration pathway. As additional
steps are added, it will become increasingly apparent how this
relates to other cell-death programs and how it might be most
effectively targeted in axonal disorders. Crucially, the lack of
any overt defects in adult Nmnat2gtE/gtE;Sarm1/ mice suggest
that if effective targeting of this pathway can be achieved, it
could potentially provide long-term relief from symptomswithout
major side effects.EXPERIMENTAL PROCEDURES
Animals, Genotyping, and Primary Neuronal Cultures
Animal work was carried out in accordance with the Animals (Scientific Proce-
dures) Act, 1986, under Project License PPL 70/7620. Primers used for PCR
genotyping of mice are listed in the Supplemental Experimental Procedures.1980 Cell Reports 10, 1974–1981, March 31, 2015 ª2015 The AuthorExplant cultures of superior cervical ganglia (SCGs) from embryonic day
18.5 (E18.5) mouse embryos and postnatal day 0 (P0) to P2 pups and dorsal
root ganglia (DRGs) from E13.5/14.5 and E17.5/E18.5 embryos and P0
pups, and dissociated SCG neuron cultures (P0–P2), were set up as described
previously (Gilley et al., 2013; Gilley and Coleman, 2010).
Neurite Outgrowth Assays
Neurite outgrowth assays were performed and quantified as described previ-
ously (Gilley et al., 2013). NAMPT inhibitor FK866 (100 nM, generously supplied
by the National Institute of Mental Health), NaAD (250 mM, Sigma-Aldrich),
NAD (1 mM, Sigma-Aldrich), or NMN (1 mM, Sigma-Aldrich) were added to
E17.5/E18.5 Nmnat2gtE/gtE DRG explant cultures at 2 days in vitro as
described.
RT-PCR Analysis and Immunoblotting
Whole brains from E18.5 mouse embryos and neurite fractions from
SCG explant cultures were processed as described previously for the
generation of RNA and/or protein extracts (Gilley et al., 2013; Gilley and
Coleman, 2010). Primers for RT-PCR, and primary antibodies and concentra-
tions for immunoblotting, are listed in the Supplemental Experimental
Procedures.
Determination of NMN and NAD Levels
NMNandNADmeasurements in whole brains from E18.5 embryos or newborn
(P0) pups, uncut or lesioned sciatic nerves from adult mice, and neurite and
ganglia fractions from DRG cultures (prepared as for SCG cultures in Gilley
and Coleman, 2010) were performed using UV-C18 high-performance liquid
chromatography (HPLC) and/or spectrofluorometric HPLC analysis essentially
as described previously (Di Stefano et al., 2014).
Microinjections, Labeling/Immunostaining, and Microscopy
Injections and quantification of neurite/cell-body survival were performed
essentially as described previously (Gilley and Coleman, 2010). Plasmids
and siRNAs injected are listed in the figure legends and in the Supplemental
Experimental Procedures.
Anterograde labeling of intercostal nerve axons with the lipophilic dye DiI
(1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate) in fixed
P0 mouse pups and whole-mount neurofilament light-chain immunostaining
of fixed diaphragms from E17.5/E18.5 embryos were performed as described
previously (Gilley et al., 2013).
Phase-contrast and fluorescence images of primary cultures and stained/
labeled tissues were acquired as described previously (Gilley et al., 2013).
Image processing is described in the Supplemental Experimental
Procedures.
Statistical Analysis
Appropriate statistical tests were performed using Prism software (GraphPad
Software). The Student’s t test, ANOVA with Tukey’s or Dunnett’s post hoc
correction (as applicable), and Pearson’s chi-square test were used in
this study. A p value > 0.05 was considered not significant, and * indicates
p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.02.060.
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